278 related articles for article (PubMed ID: 18223215)
41. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
42. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
44. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
45. Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells.
Iwabuchi E; Miki Y; Onodera Y; Shibahara Y; Takagi K; Suzuki T; Ishida T; Sasano H
Clin Exp Metastasis; 2019 Oct; 36(5):423-432. PubMed ID: 31222613
[TBL] [Abstract][Full Text] [Related]
46. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
48. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
[TBL] [Abstract][Full Text] [Related]
49. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
50. Carboplatin treatment of antiestrogen-resistant breast cancer cells.
Larsen MS; Yde CW; Christensen IJ; Lykkesfeldt AE
Int J Oncol; 2012 Nov; 41(5):1863-70. PubMed ID: 22961366
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.
Lewis-Wambi JS; Cunliffe HE; Kim HR; Willis AL; Jordan VC
Eur J Cancer; 2008 Aug; 44(12):1770-9. PubMed ID: 18614350
[TBL] [Abstract][Full Text] [Related]
52. CEACAM6 gene expression in intrahepatic cholangiocarcinoma.
Ieta K; Tanaka F; Utsunomiya T; Kuwano H; Mori M
Br J Cancer; 2006 Aug; 95(4):532-40. PubMed ID: 16868542
[TBL] [Abstract][Full Text] [Related]
53. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
54. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
55. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway.
Sukocheva O; Wang L; Verrier E; Vadas MA; Xia P
Endocrinology; 2009 Oct; 150(10):4484-92. PubMed ID: 19706837
[TBL] [Abstract][Full Text] [Related]
56. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
[TBL] [Abstract][Full Text] [Related]
57. Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells.
Al-Dhaheri MH; Shah YM; Basrur V; Pind S; Rowan BG
Steroids; 2006 Nov; 71(11-12):966-78. PubMed ID: 16949628
[TBL] [Abstract][Full Text] [Related]
58. Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.
Lee J; Kim EA; Kang J; Chae YS; Park HY; Kang B; Lee SJ; Lee IH; Park JY; Park NJ; Jung JH
BMC Mol Cell Biol; 2024 Apr; 25(1):12. PubMed ID: 38649821
[TBL] [Abstract][Full Text] [Related]
59. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence.
Redmond AM; Bane FT; Stafford AT; McIlroy M; Dillon MF; Crotty TB; Hill AD; Young LS
Clin Cancer Res; 2009 Mar; 15(6):2098-106. PubMed ID: 19276281
[TBL] [Abstract][Full Text] [Related]
60. Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E
Endocr Relat Cancer; 2019 Feb; 26(2):251-264. PubMed ID: 30557851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
